Arpida Completes Enrolment In Phase II “Intravenous-to-Oral” Switch Trial With Oral Iclaprim

Arpida’s leading product candidate is intravenous iclaprim, a potent antibacterial that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The clinical programme for the first indication, complicated skin and skin structure infections (cSSSI), has been completed. The submission of the NDA to the US FDA was completed in March 2008.

More: continued here

Filed under: Dermatology on October 1st, 2008